arrow
F

Fernanda Palhano-Fontes

University of Calgary
H指数:22
被引数:3,025

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Exploratory non-randomized clinical trial of subcutaneous esketamine in treatment-resistant depression: Effects of ketamine-assisted psychotherapy

探索性非随机对照临床试验:皮下注射艾斯氯胺酮在难治性抑郁症中的应用——氯胺酮辅助心理疗法的效果

2026-08-010
OAAI
Dissociation and antidepressant response to subcutaneous esketamine: A clinical study

皮下注射艾斯凯他明后的解离现象及抗抑郁反应:一项临床研究

2026-07-010
OAAI
An international mega-analysis of psychedelic drug effects on brain circuit function

关于致幻药物对大脑回路功能影响的一项国际性大规模分析

2026-04-060
OAAI
Inflammatory response to repeated subcutaneous esketamine in treatment-resistant depression: The role of baseline C-reactive protein

重复皮下注射右旋氯胺酮对难治性抑郁症的炎症反应:基线C反应蛋白的作用

2025-12-150
PRE
A dream EEG and mentation database

梦境脑电图(EEG)与思维数据库

2025-08-130
OA
Safety, tolerability and subjective effects of vaporized N,N-Dimethyltryptamine: A randomized double-blind clinical trial

安全性、耐受性和主观效应:一项随机双盲临床试验

2025-06-170
PRE
Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression
2025-04-011
PRE
Repeated subcutaneous esketamine on treatment-resistant depression: An open-label dose titration study
2025-01-012
PRE
Ketamine-induced altered states of consciousness: a systematic review of implications for therapeutic outcomes in psychiatric practices

氯胺酮引起的意识状态改变: 对精神病学实践中治疗结果的影响的系统评价

2024-10-280
PRE
Rapid and long-lasting effects of subcutaneous esketamine on suicidality: An open-label study in patients with treatment-resistant depression
2024-08-013
PRE
Safety and tolerability of inhaled N,N-Dimethyltryptamine (BMND01 candidate): A phase I clinical trial
2024-03-016
PRE
Moderators of ayahuasca's biological antidepressant action
2022-12-056
OAAI